A randomized, double‐blind, placebo‐controlled trial of camicinal in Parkinson's disease
Background: Delayed gastric emptying may impair ʟ-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of ʟ-dopa and symptoms of PD.
Methods: Phase II, double‐blind, placebo‐controlled trial. Participants were randomized to receive camicinal 50 mg once‐daily (n = 38) or placebo (n = 20) for 7 to 9 days.
Results: ʟ-dopa exposure was similar...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 212.0KB)
- Publisher copy:
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Marrinan et al
- Copyright date:
- © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record